Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 07h30 HE
|
Wave Life Sciences USA, Inc.
RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected...
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
09 mai 2024 07h00 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
07 mai 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
02 mai 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
30 avr. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
23 avr. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation...
Wave Life Sciences to Present at Upcoming Investor Conferences
27 mars 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
06 mars 2024 07h30 HE
|
Wave Life Sciences USA, Inc.
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and...
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
28 févr. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
27 févr. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration ...